Showing results (71-80 of 103) with videos related to
Sort By:
Pageof 11
Journal of the American College of Cardiology|October 16, 1999
Thrombin generation after the abrupt cessation of intravenous unfractionated heparin among patients with acute coronary syndromes: potential mechanisms for heightened prothrombotic potentialR C Becker, F A Spencer, Y Li, et al.The American Journal of Cardiology|July 13, 2001
Age and the utilization of cardiac catheterization following uncomplicated first acute myocardial infarction treated with thrombolytic therapy (The Second National Registry of Myocardial Infarction [NRMI-2])F A Spencer, R J Goldberg, P D Frederick, et al.Journal of Thrombosis and Haemostasis : JTH|April 17, 2012
A phase 1 ascending dose study of a subcutaneously administered factor IXa inhibitor and its active control agentJ P Vavalle, C P Rusconi, S Zelenkofske, et al.Proceedings of the National Academy of Sciences of the United States of America|April 18, 1998
The cleaved peptide of the thrombin receptor is a strong platelet agonistM I Furman, L Liu, S E Benoit, et al.Annals of Internal Medicine|April 15, 1994
Comparison of clinical outcomes for women and men after acute myocardial infarction. The Thrombolysis in Myocardial Infarction InvestigatorsR C Becker, M Terrin, R Ross, et al.Journal of the American College of Cardiology|April 1, 1995
Cardiac rupture associated with thrombolytic therapy: impact of time to treatment in the Late Assessment of Thrombolytic Efficacy (LATE) studyR C Becker, A Charlesworth, R G Wilcox, et al.Journal of Thrombosis and Thrombolysis|August 6, 1999
Ischemic preconditioning may be transferable via whole blood transfusion: preliminary evidenceE W Dickson, C P Reinhardt, F P Renzi, et al.Journal of Thrombosis and Haemostasis : JTH|February 21, 2008
A randomized, repeat-dose, pharmacodynamic and safety study of an antidote-controlled factor IXa inhibitorM Y Chan, C P Rusconi, J H Alexander, et al.Archives of Internal Medicine|March 17, 2001
Early clinical outcomes and routine management of patients with non-ST-segment elevation myocardial infarction: a nationwide perspectiveR C Becker, M Burns, N Every, et al.Oligonucleotides|September 15, 2007
Antidote-controlled platelet inhibition targeting von Willebrand factor with aptamersS Oney, S M Nimjee, J Layzer, et al.Pageof 11